The Investigation for New Discovery of Biomarkers
BioFIND is an observational clinical study designed to discover and verify biomarkers of Parkinson's disease (PD). The study is carried out at eight academic sites in the United States and began recruitment in 2012. BioFIND is collecting clinical data and biospecimens, including blood and cerebrospinal fluid (CSF), in a population of 120 well-defined, moderately advanced PD subjects and 120 healthy controls.
BioFIND follows standardized data acquisition protocols to ensure that tests and assessments conducted at multiple sites can be pooled. Data and samples acquired from study participants are placed in a comprehensive Parkinson's database and biorepository, which is available to the scientific community to conduct research on novel PD biomarkers. The study aims to complement PPMI to produce the most comprehensive and long-ranging dataset available for biomarker discovery work throughout the PD community.
Only with collaborative efforts like BioFIND can we efficiently discover and verify biomarker candidates for PD. This study is sponsored by The Michael J. Fox Foundation for Parkinson's Research with support from the National Institute of Neurological Disorders and Stroke (NINDS).
BioFIND samples are now available for request!
While study recruitment is ongoing, clinical data and biospecimens from BioFIND are now available for request. Clinical data from BioFIND is hosted at LONI. Please visit the study site at LONI to apply for expedited access to available data. More information about using the BioFIND data is found on Accessing BioFIND Data. To request access to available BioFIND samples, please complete and submit a Letter of Intent to the Access Data and Biospecimens program. A detailed review of the process can also be found on Accessing BioFIND Biospecimens.
Available Sample Requests
Researchers apply to use BioFIND biospecimens through the Access to Data and Biospecimens program. The following research studies have been approved for sample use.
|Project Title||Principial Investigator||Institution||Specimen Used|
|CRP40 Expression as a Biomarker of Parkinson's Disease||Ram Mishra, PhD||CRP40 Inc.||RNA|
|Verification of a long-noncoding RNA in blood as a biomarker for Parkinson's disease||Antony Cooper, PhD||Garvan Institute of Medical Research||RNA|
|Analysis of circulating brain-enriched microRNAs as biomarkers for Parkinson's disease||Samuil Umansky, MD, PhD||DiamiR, LLC||Plasma|
|Metabolomic analysis of Parkinsonian disorders||Peter LeWitt, MD||Henry Ford Hospital||
CSF and Plasma
|Comprehensive analysis of brain and peripheral biogenic small molecule levels in Parkinson's Disease||Omar Mabrouk, PhD||University of Michigan||
|Lysosomal enzymes activity and GBA1 genotyping in CSF of Parkinson's Disease patients: A Confirmatory Study||Lucilla Parnetti, MD, PhD||University of Perugia||
DNA and Plasma
Available Biospecimens and Data*
|Clinical Data||Whole Blood Pellet||Plasma||Saliva||Urine||DNA||RNA||CSF|
*Available resources as of March 24, 2015. Numbers refer to submission from unique individuals. Typical submissions include: clinical data, 2 whole blood pellets, 12 ml plasma from whole blood, 8.5 ml whole blood for DNA extraction, 5-10 ml whole blood for RNA extraction, 10 ml cerebrospinal fluid.
Recruitment is ongoing and sites continue to collect samples and clinical data. For the most up to date biospecimen inventory, please see the NINDS Repository Catalog.